Long-lasting and Effective Treatment of Joint Pain and Lameness

Arthramid Hydrogel

Learn More

Case Selection & Management

Learn More

Clinical Studies

Learn More

Arthramid® Vet treats non-infectious causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA).

Arthramid® Vet is a biocompatible, non-pyrogenic, neuro-innocuous injectable 2.5% cross-linked polyacrylamide hydrogel for intra-articular injection in animals. Arthramid® Vet consists of 2.5% cross-linked polyacrylamide and 97.5% water for injection.

Arthramid® Vet hydrogel acts as a dynamic tissue scaffold that increases the elasticity and load transfer capacity of the joint, restoring the joint to healthy function.


In Episode 6, Dr Leigh de Clifford discusses the Published Literature to date for the development of the use of 2.5% PAAG in treating lameness.

Episode 5

In Episode 5 we talk to Australian legend Dr Kim McKellar, Equine Veterinarian, about his experiences of Arthramid Vet from over 50 years in clinical practice; "I wish I had this product 30 years ago". 

Epidsode 4

Episode 4 We meet with Dr Aziz Tnibar, one of the original researcher's behind the use of 2.5% PAAG in the treatment of lameness and osteoarthritis in animals.

Episode 3

Episode 3 Listen to our first equine vet testimonial from Dr Marc Koene

Episode 2

This second episode in our series discusses how to use Arthramid Vet in the management of joint lameness and osteoarthritis in horses.

Episode 1

Episode 1 to introduce this exciting new treatment for joint lameness and osteoarthritis in animals.

Our Philosophy

Every detail is taken care of

“Our philosophy of innovation remains at the centre of everything we do. Our core mission is to improve the health, performance, and wellbeing of equine patients through technological innovation, intensive R & D and global partner alliances in the veterinary industry leading to better patient outcomes and client enjoyment of the animals we love.”

Case Reports

Achieving the best outcomes

Junior a Warmblood Gelding

History: Junior, a 4 year old Warmblood gelding, bred to perform dressage, presented with a progressive left forelimb lameness. Clinical signs were...

read more

Case Selection

Read More on Case Selection Criteria

Understanding the complexity of disease processes associated with joint pain remains a constant dilemma in clinical practice and as with any disease process, an accurate diagnosis is essential.

Arthritis describes inflammation of a joint and can occur after single or repetitive episodes of trauma. The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis(OA). Sub-chondral bone injury also plays a role.

These pathological conditions are ‘a group of overlapping distinct diseases which may have different aetiologies, but with similar biologic, morphologic, and clinical outcomes.

Although conventional concepts of OA emphasise the direct and predominant involvement of cartilage and bone in OA development, it is increasingly recognised that the synovium also contributes to the central pathophysiological event of cartilage matrix depletion.

Cases suitable for treatment with Arthramid®Vet are those in which lameness is localised to the joint by clinical examination, intra-articular analgesia, radiography, ultrasound, MRI, CT and/or Scintigraphy. Conditions that respond to treatment with Arthramid®Vet include acute and chronic synovitis, capsulitis, meniscal tears, OA, and subchondral bone cysts. It is essential that anamnesis of data of ongoing infection, concomitant medication, surgery or potential fracture is reviewed prior to injection to prevent possible infections or use of the product for conditions other than for which it is indicated.

Case Management

Read More on Case Management Protocols

Animals should be rested for 48 hours immediately after treatment. After this time the animal can return to exercise compared to its level of comfort.

Clinical studies show that tissue integration and subsequent augmentation of the joint capsule takes between 2 and 4 weeks to occur, although a response to treatment can be seen earlier than that in some cases.

Animals typically show a gradual reduction in lameness during the first week after treatment and a concurrent reduction in reaction to passive flexion. This continues to improve over the ensuing 2 to 3 weeks. By 4 weeks no further improvement is expected. Re-examination at 4 weeks is therefore indicated to either administer a second dose – in those that have only partially responded- or to reassess accuracy of the diagnosis.

It is important for owners to understand the time lag for a treatment effect to be seen as this contrasts with conventional therapies. In this respect and due to its long lasting effect it may also be prudent to consider treating the animal during periods of reduced exercise demands or early on in the animals training programme.

Mode Of Action

Not All Hydrogels Are The Same

PAAG products, although often considered equal, have clear differences in composition, manufacturing and injection techniques as well as their ability to interact with surrounding tissues. Characteristics that determine the safety and effectiveness of each hydrogel.

Upon injection into joints, the Arthramid® Vet, a uniquely cross-linked 2.5% polyacrylamide hydrogel, adheres to the synovial lining through its ability to exchange water molecules. The ensuing influx of mononuclear cells reduces exposure of synoviocytes to pro-inflammatory cytokines in the inflamed or diseased joint. The gel becomes progressively integrated into the synovial lining and its immediate surrounding tissue of the inner joint capsule by a combination of cell migration and vessel ingrowth forming a thick, cushion-like membrane, over 14 to 28 days, consisting of vessel integrated gel covered by a new and hypercellular synovial cell lining.

Arthramid®Vet, therefore, has an augmentation effect on the joint capsule and synovium, increasing elasticity and tensile strength and improving its capacity to transfer load. This augmentation and cushioning causes a subsequent reduction in mechanoreceptor and nociceptor activation in the capsule itself. In turn, this further reduces synovitis and its successively deleterious effects as a result.

Unlike other hydrogels, Arthramid®Vet becomes fully integrated into the surrounding tissue (rather than encapsulated) and is therefore long-lasting. Arthramid®Vet does not elicit a foreign body reaction or harbour infection.

User Guide Download

Arthramid Vet User Guide
Download User Guide : Arthramid Vet User Guide

Comments From Clinical Practice

Dr Kim Mckellar

I have been using Arthramid Vet for 4 years treating TB’s, SB’s and equestrian horses. 90% of my work is lameness identification and treatment. I have injected over 600 joints with Arthramid Vet and have experienced no side effects. (read more)

Dr Marc Koene

I was one of the first vets to use Arthramid worldwide and have now used Arthramid for over 10 years in our clinic. We have injected over a thousand horses and have found it to be very safe. (read more)

Dr Marcus Allan

Arthramid Vet enables me to effectively manage joints that have mild, moderate or severe osteoarthritic changes for a prolonged period of time with very little chance of having an adverse reaction, even in those patients with other disease processes occurring concurrently.  (read more)

Get In Touch

I am Interested In

Order Request

32 Hill Road, Cambridge, NZ
Phone +64 (09) 8013 253

Arthramid Vet Australia

Registered in New Zealand to: Innovative Medical Solutions Limited NZBN: 9429041325544, 32 Hill Road, Cambridge 3494, New Zealand. Registered pursuant to the ACVM Act 1997 Number A11596. See www.foodsafety.govt.nz  for registration conditions.

32 Hill Road, Cambridge
PO Box 1083, Cambridge 3450
Phone +64 (09) 8013 253